Trial Profile
Evaluation of docetaxel, estramustine, phosphate and bortezomib (DEB) in patients with androgen independent prostate cancer (AIPCa): A phase I/II study with molecular endpoints
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 02 Feb 2006
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Docetaxel (Primary) ; Estramustine (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Feb 2006 New trial record.